Takeda (TAK) announced the U.S. availability of Gammagard Liquid ERC with less than or equal to two microgram/mL IgA in a 10% solution, by prescription, approved as replacement therapy for people two years of age and older with primary immunodeficiency. Gammagard Liquid ERC is a liquid immunoglobulin therapy that does not require reconstitution and has a low immunoglobulin A content less than or equal to two microgram/mL in a 10% solution to be administered intravenously or subcutaneously.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Takeda Targets Chinese Pediatric Market With New Teduglutide Study in Short Bowel Syndrome
- Takeda’s TAK-411 CIDP Study Progresses: What Investors Should Watch
- Takeda’s Entyvio Community Trial: What Ongoing Phase 4 Data Could Mean for TAK Investors
- Largest borrow rate increases among liquid names
- Takeda resumed with an Overweight at Morgan Stanley